The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

由苏州大学第一附属医院妇产科的Fang Wang，Yi Zhang，Jinhua Zhou 团队发表的名为“A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

PARP inhibitors, such as olaparib, have demonstrated fantastic results for some men. However, not all men respond to this drug, and for those that do, their cancer eventually develops resistance.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are promising cancer treatments because they block a ... eliminate malignant cells depends on several factors that scientists should keep in mind ...

AZ and Merck's drug was also approved as a second-line ... but it is the first and only PARP inhibitor that has demonstrated superior rPFS compared to chemotherapy, which is today the standard ...

The combination therapy approval from the US Food and Drug Administration (FDA ... biology and bringing a targeted therapy like a PARP inhibitor will hopefully move the needle.” ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized starting doses, may improve patient outcomes.

The EMA’s human medicines committee has recommended approval for Akeega, a fixed-dose combination of J&J’s PARP drug Zejula (niraparib) and androgen inhibitor Zytiga (abiraterone acetate), in ...

Antibodies have been used as anticancer drugs for more than 20 years and ... and safety—with those of DDR therapies, such as PARP inhibitors, that target DDR deficiencies, explained Campbell.